Developing new agents that target calcium-sensing receptors for kidney disease treatment
Official title: Design of Calcium-sensing Receptor Targeted Thera(g)nostic Agents
Funded at Inlighta Biosciences, LLC · NIH-11006566 · Data updated 2026-11-12
This study is looking at a special protein that helps control calcium levels in the body, which is important for people with adult polycystic kidney disease (ADPKD), and aims to create new medicines that can boost its activity to help improve kidney function and slow down the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inlighta Biosciences, LLC NIH-funded |
| Lab location | 1 site (Marietta, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $323,743 |
| NIH project number | 1R41DK139927-01A1 |
| Project ID | NIH-11006566 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with adult polycystic kidney disease (ADPKD) who may benefit from targeted therapies.
✕Less likely to help
Patients with conditions unrelated to calcium-sensing receptor dysfunction or those not diagnosed with ADPKD may not receive any benefit from this research.
What this research studies
This research focuses on the calcium-sensing receptor (CaSR), which plays a crucial role in regulating calcium levels in the body and is linked to various diseases, including adult polycystic kidney disease (ADPKD). The researchers aim to create new therapeutic agents that can specifically target CaSR, enhancing its activity to improve kidney function and reduce disease progression. By understanding how CaSR behaves in different conditions, they hope to develop drugs that are both effective and have fewer side effects. The study will involve designing and testing new compounds that can act as either agonists or antagonists of CaSR.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve kidney health and quality of life for patients with ADPKD.
How similar studies have gone: While the approach of targeting calcium-sensing receptors is promising, it is relatively novel and has not been extensively tested in the context of ADPKD.
Where this research is happening
-
Inlighta Biosciences, LLC
Marietta, United States Active
Researchers
- Principal investigator: Yang, Jenny J. — Inlighta Biosciences, LLC
- Study coordinator: Yang, Jenny J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.